# CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

> **NCT03710421** · PHASE1 · RECRUITING · sponsor: **City of Hope Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **PROCEDURE:** CS1-CAR T Therapy
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **PROCEDURE:** Leukapheresis

## Key facts

- **NCT ID:** NCT03710421
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-04-23
- **Primary completion:** 2027-02-23
- **Final completion:** 2027-02-23
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710421, "CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03710421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*